|
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of the current study was to evaluate the sensitivity and specificity of INSM1 ICC on direct smears (DS) from patients with SCLC in comparison with IHC on small biopsies (SBs).
|
31343851 |
2019 |
|
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although INSM1 is reportedly the most specific marker of SCLC, its sensitivity is not superior to p16 or composite marker CD56 + TTF1 + p16.
|
30385371 |
2019 |
|
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulinoma-associated protein 1 is a novel diagnostic marker of small cell lung cancer in bronchial brushing and cell block cytology from pleural effusions: Validity and reliability with cutoff value.
|
31436913 |
2019 |
|
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
INSM1 was positive in 92.3% of prostatic SCCs, compared with 53.8% positive for chromogranin, and 84.6% positive for synaptophysin.
|
29885405 |
2018 |
|
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Shh signaling pathway activates INSM1 expression through N-myc and Ascl1 in aggressive SCLC.
|
29501727 |
2018 |
|
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, the reciprocal expression of INSM1 and YAP1 appears to stratify SCLC into distinct subgroups and may be useful, along with <i>RB1</i> mutation status, to identify chemo-refractory SCLC patients.
|
29088741 |
2017 |
|
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our results argue that LSD1 plays an important role in neuroendocrine-associated transcription and cell proliferation of SCLC via interactions with the SNAG domain proteins INSM1 and GFI1B.
|
28667074 |
2017 |
|
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Insulinoma associated-1 (INSM1) gene is expressed exclusively in early embryonic neuroendocrine tissues, but has been found highly re-activated in most of the neuroendocrine tumors including small cell lung carcinoma.
|
27072116 |
2016 |
|
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we found that INSM1 was not expressed in non-small-cell lung cancer and some SCLC cell lines expressing Notch1-Hes1.
|
26482608 |
2015 |
|
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
CTD_human |
Selective inhibition of tumor oncogenes by disruption of super-enhancers.
|
23582323 |
2013 |
|
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Despite this, the INSM1 promoter activity was found to be unchanged or increased in SCLC chemoresistant cells and xenografts compared to chemosensitive variants.
|
22576955 |
2012 |
|
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
INSM1, SGNE1 and H2AFZ are typical for small cell lung cancer.
|
20332665 |
2010 |
|
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This INSM1 promoter region showed very high levels of expression in most of the SCLC cell lines and expression was absent in cell lines of non-neuroendocrine origin.
|
16052225 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although INSM1 might be a meaningful adjunct in the differential diagnosis of neuroendocrine neoplasias, a general uncritical vote for replacing the traditional markers by INSM1 may not be justified.
|
30358615 |
2020 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
INSM1 was negative in all but 1 of 91 analyzed non-neuroendocrine tumors (adenocarcinomas, squamous cell carcinomas; specificity: 99%).
|
30358615 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
|
31077609 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results show that parathyroid hormone and chromogranin A are useful markers for parathyroid neoplasms, while synaptophysin and INSM1 are not very sensitive broad-spectrum markers for these neoplasms.
|
31119524 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Next, we sought to dissect how the ADK pathway contributes to NB tumor cell growth in the context of INSM1 expression.
|
30755485 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
|
30523500 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study aimed to characterize the immunohistochemical profile of INSM1 in a cohort of peripheral neuroblastic tumors and compare INSM1 expression in these tumors to that seen in other embryonal neoplasms, using both tissue microarrays and whole-slide histologic sections.
|
30975032 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Insulinoma-associated-1 (IA-1 or INSM1) encodes a zinc-finger transcription factor, which was isolated from a human insulinoma subtraction library, with specific expression patterns, predominantly in developing neuroendocrine tissues and tumors.
|
31113827 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
INSM1 was positive in 90 (99%) of the NET/TNEFs and negative in 32 (97%) non-NETs.
|
30502379 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have shown that INSM1 is a sensitive marker for neuroendocrine tumours.
|
31077609 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulinoma-associated 1 (INSM1) has recently been reported as a highly sensitive and specific marker that displays positivity in ~90%-100% of poorly differentiated pulmonary neuroendocrine tumors.
|
30385371 |
2019 |